This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Solomon, A. W. Articles by Mabey, D. C. W. Search for Related Content PubMed PubMed Citation Articles by Solomon, A. W. Articles by Mabey, D. C. W.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, October 2004, p. 982-1011, Vol. 17, No. 4
0893-8512/04/$08.00+0     DOI: 10.1128/CMR.17.4.982-1011.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Diagnosis and Assessment of Trachoma

Clinical Research Unit, London School of Hygiene & Tropical Medicine, London, United Kingdom,¹ Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland,² National Microbiology Laboratory, Health Canada, Winnipeg, Canada³

Trachoma is caused by Chlamydia trachomatis. Clinical grading with the WHO simplified system can be highly repeatable provided graders are adequately trained and standardized. At the community level, rapid assessments are useful for confirming the absence of trachoma but do not determine the magnitude of the problem in communities where trachoma is present. New rapid assessment protocols incorporating techniques for obtaining representative population samples (without census preparation) may give better estimates of the prevalence of clinical trachoma. Clinical findings do not necessarily indicate the presence or absence of C. trachomatis infection, particularly as disease prevalence falls. The prevalence of ocular C. trachomatis infection (at the community level) is important because it is infection that is targeted when antibiotics are distributed in trachoma control campaigns. Methods to estimate infection prevalence are required. While culture is a sensitive test for the presence of viable organisms and nucleic acid amplification tests are sensitive and specific tools for the presence of chlamydial nucleic acids, the commercial assays presently available are all too expensive, too complex, or too unreliable for use in national programs. There is an urgent need for a rapid, reliable test for C. trachomatis to assist in measuring progress towards the elimination of trachoma.

This article has been cited by other articles:

• Pepin, J., Deslandes, S., Frost, E., Andreassen, A. A., Solomon, A. W, Bailey, R., Mabey, D. C W (2008). Absence of Mycoplasma genitalium in eye samples from a trachoma-endemic area of Tanzania. Br. J. Ophthalmol. 92: 435-435 [Full Text]  
• Burton, M. J. (2008). Trachoma: an overview. Br Med Bull 0: ldm034v1-18 [Abstract] [Full Text]  
• Ngondi, J., Matthews, F., Reacher, M., Onsarigo, A., Matende, I., Baba, S., Brayne, C., Zingeser, J., Emerson, P. (2007). Prevalence of Risk Factors and Severity of Active Trachoma in Southern Sudan: An Ordinal Analysis. Am J Trop Med Hyg 77: 126-132 [Abstract] [Full Text]  
• Zinkernagel, M., Catalano, E., Ammann-Rauch, D. (2007). Late-stage inclusion body conjunctivitis: trachoma?. Br. J. Ophthalmol. 91: 402-403 [Full Text]  
• Shapiro, B, Dickersin, K, Lietman, T (2006). Trachoma, antibiotics and randomised controlled trials.. Br. J. Ophthalmol. 90: 1443-1444 [Full Text]  
• Lietman, T. M., Gaynor, B., Porco, T., Solomon, A. W., Foster, A., Mabey, D. C.W. (2005). Single-Dose Azithromycin for Trachoma. NEJM 352: 414-415 [Full Text]